M&A
confidence high
sentiment positive
materiality 0.75
Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M
Kymera Therapeutics, Inc.
- Up to $750M total payments including $85M upfront/option exercise payments.
- Tiered royalties ranging from high-single-digit to mid-teens on net sales.
- Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.
- CDK2 degraders target breast cancer and other solid tumors.
- Agreement announced June 25, 2025.